GRIPHON 2 / Protocol AC-065A302

• Research type

  Research Study

• Full title

  A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension.

• IRAS ID

  35873

• Contact name

  Simon JR Gibbs

• Eudract number

  2009-014490-41

• ISRCTN Number

  NA

• Research summary

  GRIPHON 2 Study: The main purpose of this clinical research study is to show that treatment with this new drug (ACT-293987) can improve the ability to exercise in patients with pulmonary arterial hypertension (PAH) and to show that it can delay the time to worsening of the disease. Men and women above the age of 18 with PAH are invited to participate in this clinical research study that will be performed in specialist centres of excellence in the UK and other clinics around the world in 20 countries. The study will include approximately 272 patients. The study will last approximately 4 years. During that time participants will have their exercise ability assessed regularly along with blood pressure, heart performance, blood tests and quality of life.

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  09/H0707/95

• Date of REC Opinion

  23 Mar 2010

• REC opinion

  Further Information Favourable Opinion